Research News - Dravet Syndrome Foundation

Woman researcher using microscope in lab

The humanistic and economic burden of Dravet syndrome on caregivers and families: Implications for future research

(Jensen, et al. 2017). A team of physicians from Washington, the United Kingdom, Colorado, and Zogenix, Inc. reviewed the published literature on the burden of Dravet syndrome (DS) on caregivers and families. Instead of examining diagnostic criteria, treatment/management, seizure control, etc., they looked specifically for how DS affects the caregiver and families both humanistically and economically. […]

The humanistic and economic burden of Dravet syndrome on caregivers and families: Implications for future research Read More »

Optimizing the Diagnosis and Management of Dravet syndrome: Recommendations from a North American Consensus Panel

Research News / By Nicole Villas

(Wirrell, et al. 2017). A panel of experts on Dravet syndrome including 13 physicians and 5 family members of patients with Dravet syndrome in North America answered a series of in-depth surveys about the presentation, diagnosis, and treatment of Dravet syndrome. Consensus was obtained in many areas including presentation during the first years of life;

Optimizing the Diagnosis and Management of Dravet syndrome: Recommendations from a North American Consensus Panel Read More »

Adult motor phenotype differentiates Dravet syndrome from Lennox-Gastaut syndrome and links SCN1A to early onset parkinsonian features

Research News / By Nicole Villas

(Aljaafari, et. al. 2017). In this brief communication, published in Epilepsia, the authors examined the motor differences between 14 adult patients with Dravet syndrome (DS) and 14 adult patients with Lennox-Gastaut syndrome (LGS). They chose Lennox-Gastaut because previous findings showed that adult patients with DS exhibited early-onset parkinsonian features, and they wanted to determine whether

Adult motor phenotype differentiates Dravet syndrome from Lennox-Gastaut syndrome and links SCN1A to early onset parkinsonian features Read More »

Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome

Research News / By Nicole Villas

(Griffin, et. al 2017). Building on previous drug screening in a Dravet syndrome model of zebrafish that identified clemizole, a histamine (H1) receptor antagonist, as having anti-epileptic properties, this study sought to further examine the mechanisms of clemizole\’s action and expand the class of serotonin-acting compounds to include, among others, the FDA-approved drugs lorcaserin (Belviq) and

Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome Read More »

The humanistic and economic burden of Dravet syndrome on caregivers and families: Implications for future research

Optimizing the Diagnosis and Management of Dravet syndrome: Recommendations from a North American Consensus Panel

Adult motor phenotype differentiates Dravet syndrome from Lennox-Gastaut syndrome and links SCN1A to early onset parkinsonian features

Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome

Dravet Syndrome

Caregivers

Get Involved